



Vaccines: current insights and developments

“Learn from the past, act in the present and prepare for the future”

VACCINOLOGY
MASTER CLASS



Een programma voor zorgprofessionals in de infectieziekten bestrijding

Een tweedaagse Vaccinology Masterclass 23 en 24 september 2021 in Almere.

Het programma geeft een overzicht van de wetenschappelijke stand van zaken op het gebied van de ontwikkeling van vaccins en de toepassing ervan met een focus op het belang van de mucosale afweer, de mogelijk ongewenste effecten van vaccineren, de toepassing van vaccins in ontwikkelingslanden en de ontwikkeling van nieuwe vaccins voor respiratoire virussen. Uiteraard is er ook uitgebreid aandacht voor de laatste ontwikkelingen en inzichten omtrent COVID-19.

Datum: donderdag 23 en vrijdag 24 September 2021
Ontvangst donderdag vanaf 8.30 uur.

Locatie

Van der Valk hotel, Veluwezoom 45 Almere. Dichtbij de A6 en goed bereikbaar per openbaar vervoer.

Online

Online deelname is eveneens mogelijk. Beide dagen worden live gestreamd met een chatfunctie voor interactieve deelname. (Meer info zie ook bij inschrijving)


Programma

De inhoud van het programma is samengesteld door de Faculty van de Stichting Vaccinology Masterclass onder voorzitterschap van prof. dr. Ronald de Groot, kinderarts-infectioloog/immunoloog, Radboud UMC, Nijmegen.

Accreditatie gehonoreerd met 12 punten

Doelgroepen

Kinderartsen, internisten, infectiologen, medisch microbiologen, artsen infectieziekten bestrijding, immunologen, jeugdartsen, geriateren, apothekers en overige geïnteresseerden.




Introductie:

De Stichting Vaccinology Masterclass organiseert elk jaar een tweedaagse nascholing voor specialisten in het veld van de infectieziekten, microbiologie en immunologie. De afgelopen maanden is de wereld onomkeerbaar veranderd door de COVID-19 pandemie. Hierbij is het voor iedereen duidelijk geworden dat inzicht in het ontstaan en de verspreiding van nieuwe infectieziekten, snel-diagnostiek, optimale behandeling en preventie essentieel zijn voor de borging van de volksgezondheid. Kennis van reeds bekende infectieziekten en de wijze waarop deze kunnen worden voorkomen vormt de basis voor een op wetenschappelijke basis geschoeid effectief beleid.

In het programma van de tweedaagse van dit jaar komen verschillende aspecten van het vaccineren aan bod met een focus op het belang van de mucosale afweer, de mogelijk ongewenste effecten van vaccineren, toepassing van vaccins voor ontwikkelingslanden en de ontwikkeling van nieuwe vaccins voor respiratoire virussen. Uiteraard is er ook uitgebreid aandacht voor de laatste ontwikkelingen en inzichten omtrent COVID-19.

We kijken uit naar uw deelname aan deze energieke, interactieve en leerzame bijeenkomst.

Vriendelijke groet
Prof. dr. Ronald de Groot, voorzitter
Stichting Vaccinology Masterclass



Stichting Vaccinology Masterclass

De Stichting heeft twee doelen: ten eerste het bevorderen van onderwijs en opleiding op het gebied van vaccins en de toepassing daarvan; ten tweede het organiseren van cursussen, masterclasses en trainingen voor studenten en professionals werkzaam in de gezondheidszorg en het verrichten van al wat hiermee verband houdt of daartoe bevorderlijk kan zijn. De Stichting heeft geen winstoogmerk en heeft de ANBI status.

BESTUUR


- ✚ Prof. dr. Ronald de Groot, voorzitter
- ✚ Dr. Gerben Ferwerda, secretaris
- ✚ Dr. Nico Hartwig, penningmeester
- ✚ Dr. Nicoline van der Maas, arts Maatschappij en Gezondheid/epidemioloog
- ✚ Dr. Patricia Bruijning-Verhagen, kinderarts-epidemioloog
- ✚ Mr. Cees Gips, bestuurslid

FACULTY LEDEN:

Prof. Dr. Ronald de Groot, kinderarts-infectioloog/immunoloog
Dr. Nicoline van der Maas, arts Maatschappij en Gezondheid / epidemioloog
Dr. Hans Rümke, medisch vaccinoloog
Dr. Patricia Bruijning-Verhagen, kinderarts-epidemioloog
Dr. Gerben Ferwerda, internist-immunoloog/allergoloog
Prof. Dr. Maarten Postma, Global Health Economics en hoogleraar Pharmacoeconomics
Drs. Henrike ter Horst, jeugdarts KNMG
Dr. Nico Hartwig, kinderarts-infectioloog
Dr. Wendy Unger, immunoloog
Drs. Marie José Sprakel, arts Maatschappij en Gezondheid, jeugdarts KNMG
Dr. Roderick Venekamp, huisarts/epidemioloog


Ondersteunend congresburo:

Bruggink Communicatie Support
Gerhard Bruggink, directeur
Doraweg 3, 8531 PW Lemmer,
T 0514-533280/06-21424899
info@gerhardbruggink.nl




VACCINOLOGY MASTERCLASS

Program thursday 23 september 2021		
8.30 - 9.30	Walk-in and registration	
Mucosal immunology and vaccines		
09.30	Wendy Unger	Opening by the chairman
9.40-10.20	Martijn Nolte	Should I stay or should I go? <i>On the migration and maintenance of antigen-experienced T-cells</i>
10.25-11.15	Nils Lycke	Benefits of mucosal vaccination and the ability to protect against pandemic infections: <i>Current thinking and trends in mucosal vaccine development</i>
11.15-11.40	Pause	
11.45-12.30	Debby Bogaert	The human microbiome and vaccination: <i>who affects whom?</i>
12.30-13.40	Lunch	
Vaccines: more than meets the eye		
13.40	Henrike ter Horst	Propositions in advance opening by the chairman
13.50-14.20	Gerben Ferwerda	Vaccination and allergies, is there a connection?
14.25-15.00	Willem van Eden	Molecular mimicry in vaccination
15.05-15.25	Pause	
15.30-16.10	Rik de Swart	The measles paradox explained: how measles virus suppresses and activates the immune system
16.15-16.55	Hanneke Schuitemaker (online bijdrage)	Novel Adenoviral vector platform for the development of a COVID-19 vaccine
17.00-17.30	Henrike ter Horst	Propositions afterwards, interactive discussion.
17.30-18.00	Chat and drinks	
18.00-18.15	Appetizer in the hall	
18.15-19.00	Rosanne Hertzberger	Don't become tone deaf: <i>How the citizen perspective is missing in the scientific discourse on vaccination.</i>
19.00	Main course and dessert in the restaurant	




Program friday 24 september 2021		
Developing vaccines for developing countries		
08.55	Nico Hartwig	Opening by the chairman
9.00-9.40	Nigel Curtis	BCG – trials and tribulations
9.45-10.20	Erwin Duizer	New vaccines in the polio eradication endgame
10.25-10.45	Pause	
10.45-11.25	Matthijs Jore	Malaria vaccine: are we almost there?
11.30-12.00	Meta Roestenberg	The role of controlled human infection studies in vaccine development
12.00-13.20	Lunch	
Our (near) future with SARS CoV-2 and RSV...		
13.20	Patricia Bruijning Verhagen	Opening by the chairman
13.25-14.05	Louis Bont	RSV vaccination within reach?
14.10-14.50	Susan van den Hof	Monitoring and evaluation of the covid pandemic and the vaccination campaign
15.00-15.20	Pause	
Keynote lecture		
15.20-16.10	Bart Haagmans	A novel coronavirus in China: <i>a story from the frontlines</i>
16.15-16.45	Closing with a drink	





Dr. Martijn A. Nolte Principal Investigator at the Laboratory of Molecular Cell Biology Sanquin.
Per 1 september 2021 senior programma manager ZonMw

- 1997 - 2002
 Department: PhD at the Free University in Amsterdam
 Promotor: Molecular Cell Biology, VU Medical Center
 Copromotor: Prof. Dr. Georg Kraal
 Title of thesis: Dr. Reina Mebius
 Compartments, Cells and Molecules in the Spleen.
- 2002 - 2004
 Department: Postdoctoral fellow at Academic Medical Center, Amsterdam
 Department head: Hematology / Experimental Immunology
 Title research: Prof. Dr. Rien van Oers / Prof. Dr. Rene van Lier
 The Function of CD27 on Hematopoietic Stem Cells.
- 2004 - 2006
 Department: Postdoctoral fellow at Cancer Research UK, London, United Kingdom
 Department head: Immunobiology Lab
 Title research: Dr. Caetano Reis e Sousa
 Dendritic Cells and their Environment.
- 2006 - 2010
 Department: Principal Investigator at Academic Medical Center, Amsterdam
 Department head: Experimental Immunology
 Title research: Prof. Dr. Rene van Lier
 The Influence of the Activated Immune System on Hematopoiesis.
- 2011 - 2018
 Lab: Principal Investigator/Head of Laboratory at Sanquin Amsterdam
 Department: Adaptive Immunity Lab
 Department head: Hematopoiesis
 Title research: Dr. Marieke von Lindern
 T cell Immunity and its Impact on Hematopoiesis.
- 2018 - sept 2021:
 Lab: Principal Investigator at Sanquin Research, Amsterdam
 Department: Lab of Molecular Cell Biology & Core Facility
 Department head: Molecular & Cellular Hemostasis
 Research focus: Prof. Dr. Sander Meijer
 Microscopy, Adaptive Immunity, Leukocyte migration
- Current:
 Senior program manager ZonMw.






Prof. Nils Lycke MD PhD

Professor of Clinical Immunology at the Sahlgrenska University Hospital Gothenburg Sweden. Professor Nils Lycke is the principal investigator of several internationally recognized projects focused on Mucosal Immunity and Tolerance where he is a leading researcher in the field.

He has published over 180 original peer-reviewed papers and 35 reviews or book chapters. Lycke et. al. have pioneered the development of mucosal vaccines with important contributions to the field in adjuvant construction, including the patented CTA1-DD adjuvant.

Basic mechanism of mucosal immune regulation, vaccine development and clinical assessment of safety & efficacy are other main research areas. He has been the coordinator of 6 EU-sponsored projects and has received financial support from EU, NIH, Wellcome Trust, Swedish Cancer foundation, Knut and Alice Wallenberg Foundation, The Swedish Strategic Research Foundation and the Swedish Research Council, and others. As a member of the WHO Transdisease Vaccinology Steering Committee for many years, Lycke has been deeply involved in vaccine design and development as well as interacting with industry and regulatory authorities. He has been an active contributor to many international and national conferences on the topic of mucosal immunity and tolerance. He has also organized several international meetings, including two Keystone symposia, The European Mucosal Immunology Group (he is also founder of EMIG), The International Mucosal Immunology Congress (SMI). The World Congress of Immunology (Stockholm), as well as being an invited speaker at congresses of national societies, such as the British, German, Italian and Irish immunology societies. Prof. Lycke has been a plenary speaker at various meetings including: EMIG in Prag 2006, ICMI in Tokyo 2007, EMIG in Milan 2008, Nobel forum on IBD 2008, European Immunology Congress Glasgow 2008, Berzelius Conference in Stockholm 2008, ICMI in Boston 2009, European Immunology Congress Berlin 2009, EMIG in Amsterdam 2010, EFSO Paris 2010, Adjuvants and Vaccines Dublin 2010, SSI Geilo 2011, ICMI Paris 2011, EFSO Spain 2011 and RIKEN IMS-RCAI/JSI International Symposium Yokohama, Japan 2013, ICMI in Berlin, Germany, 2016 and Brisbane, Australia in 2019. IUIS congress in Beijing, China in 2019. He is also an invited lecturer to many universities, including Scandinavian universities, the NIH and Pasteur Institute (Paris and Shanghai/China) and Imperial College (London).






Prof. Debby Bogaert, MD, PhD

Chair of Paediatric Medicine, University of Edinburgh
Honorary consultant Royal Hospital for Sick Children
Center for Inflammation Research.
The Queen's Medical Research Institute
Edinburgh BioQuarter 47 Little France Crescent

Prof. dr. Debby Bogaert joined the Centre for Inflammation Research in September 2016. She worked since 2008 as a physician scientist at the Department of Pediatric Immunology of the UMC Utrecht, The Netherlands. There she initiated several ecological studies of the upper respiratory tract microbiome in relation to pathogenesis and prevention of respiratory infections. A Veni and Vidi career grant (NWO) and Top grant (ZonMW) have led to the validation and adaptation of a metagenomic pipeline for analysis of low-density respiratory microbiota, the set-up of applied bio-informatic methods and the first analyses of environmental effects on such microbiota including mode of delivery, breastfeeding and outcome. Furthermore, she participates in and facilitates microbiological and immunological research projects linked to clinical studies. In the past she worked from 2006 to 2008 as a postdoctoral fellow (Professor M Lipsitch and Professor R Malley, Harvard School of Public Health/Boston Children's Hospital) where she executed *in vitro* and animal studies on susceptibility of infants to pneumococcal colonization and infection, with specific emphasis on host-immunity. She obtained her PhD degree cum laude from the Erasmus University in Rotterdam, Netherlands (Supervisors: Professor R de Groot, Professor P Hermans, 1999-2004), for her studies on pathogenesis of pneumococcal infections, focusing on (molecular) epidemiology of bacterial colonization of the upper respiratory tract. Amongst others, she was one of the first to obtain epidemiological evidence for *in vivo* bacterial interactions occurring at the nasopharyngeal niche. In parallel, she was also trained as a pediatrician at the Sophia Children's Hospital in Rotterdam, obtaining her license in 2006. She obtained her licence as Paediatric Infectious Diseases and Immunology Specialist at the Wilhelmina Children's Hospital, Utrecht in 2014.

My research group has a major focus on investigating the physiology and pathophysiology of respiratory infections and inflammation from an ecological perspective, with the ultimate goal to design new or improved treatment and preventive measures for respiratory infections in susceptible populations. To this purpose, the team uses a fully translational approach, combining epidemiological, molecular microbiological, immunological and systems biology approaches to answer their research questions. Moreover, we execute mechanistic studies *in vitro* and *in vivo*. She still has a research team in Utrecht, the Netherlands, working on continuation of several birth cohorts and clinical studies.





Dr. Gerben Ferwerda


Internist-researcher, studied medicine at the Faculty of Medicine of the VU University in Amsterdam (cum laude). He then continued his training as a doctor-researcher, a combination of Internal Medicine and PhD research, at the Radboud University Medical Center in Nijmegen. During this period, he also worked at the Sir William Dunn School of Pathology, Oxford University, UK. After completing his doctoral research on 'cross-talk of inflammatory pathways for pathogen recognition', he accepted a full-time position as a senior researcher at the Laboratory of Infectious Diseases (LKI) at the Radboud umc in 2009. At the LKI he leads the research into respiratory viral infections. The main focus of this group is (primary) serious respiratory infections in young children. The aim is to understand the innate immunological mechanisms underlying the development of a serious disease. For this purpose, a regional clinical network has been built and a biobank has

been constructed with samples from young children (<12 months) with an acute low respiratory tract infection. Combining transcriptome analysis of leukocytes with functional immunoassays, inflammatory pathways involved in a serious disease course and potential new biomarkers have been identified. This research was conducted within the VIRGO consortium (www.virgo.com). Based on these findings, two research lines are currently underway:

1. The effect of maternal antibodies on the induction of the (innate) immune response during (primary) RSV infections in young children.

We are studying this in the context of the development of maternal vaccination.


2. The role of colonizing bacteria of the respiratory tract (microbiome) in the induction of the innate immune response during acute lower respiratory tract infection and its effect on the severity of the disease. Understanding this mucosal immune response during viral infections is being used to develop new diagnostic and prognostic tests.



Prof. Dr. W. van Eden, MD, PhD

Willem van Eden is an immunologist and medical microbiologist. After his promotion time in Leiden (promoter Jon J. van Rood), he won two prizes. In 1983 he received a prestigious Bruno Mendel fellowship from the English Royal Society. This allowed him to conduct research for two years in Israel (with Irun Cohen) at the renowned Weizmann Institute of Science in Rehovot. In 1984 he was elected winner of the Prix Zambon Benelux for his work in the field of infectious diseases pathology.

After returning from Israel, he attracted attention due to two simultaneous publications in the top medical journal Lancet.



This prompted de Volkskrant to pay extensive attention to his work on the possible relationships between infectious and autoimmune diseases. In 1988 it was discovered by van Eden and colleagues that stress proteins are fundamental for maintaining self-tolerance. Partly the result of serendipity. The publication in Nature was subsequently one of the 100 most cited publications in biomedical literature for two years. Building on this finding, Van Eden and his group are working on a vaccine against chronic inflammatory diseases based on heatshock proteins.

Van Eden is Scientific Director of the university spin-off company Trajectum Pharma and coordinated four EU consortia. Van Eden's activities focus on both the veterinary and the human domain. Until recently he was a member of the health council (committee National Vaccination Program and the Standing Committee on Infection and Immunity) and is a member of EVAG, the standing committee on European vaccine policy, of the European Center for Disease Prevention and Control (ECDC).




Dr. Rik L. de Swart

Rik de Swart studied Biology in Utrecht (completed in 1990) and obtained his PhD from Erasmus University Rotterdam in 1995. As postdoc he studied the effectiveness of different candidate measles vaccines in a monkey model. He now works as an Associate Professor at the Viroscience department of Erasmus MC. His studies focus on dissecting the pathogenesis of measles virus, respiratory syncytial virus and human metapneumovirus, with particular attention to interactions between these viruses and the host immune system. A recurring research theme is the identification of correlates of protection or disease. He uses recombinant viruses expressing fluorescent reporter proteins *in vitro* (in cell culture models) and *in vivo* (in animal models) to identify infected cells with high sensitivity. His group identified the main target cells of measles virus during the early and late stages of disease. In addition, a model was developed that can explain the measles paradox: the virus simultaneously induces immune activation and immune suppression. His research group showed that measles virus preferentially infects and depletes memory cells of the immune system, leading to "Immune amnesia". During the COVID-19 pandemic his group became actively involved in development of animal models, assessment of SARS-CoV-2-specific cellular immune responses and development of a prophylactic fusion inhibitory lipopeptide for intranasal delivery.

Rik de Swart was recently involved in revision of the measles module of the WHO series "Immunological basis for immunization"

(<https://www.who.int/immunization/documents/ISBN9789241516655/en/>), and at organizing the exhibition "Vaccination Yes! / No?" At Natural History Museum Rotterdam.

See also "De mazelenparadox verklaard: Hoe mazelenvirus het afweersysteem zowel verzwakt als activeert" in Ned Tijdschr Geneeskd 164: D4626 (2020). PMID 32395944.





Prof. Dr. Hanneke Schuitemaker, Ph.D., works in the Global Head Viral Vaccine Discovery and Translational Medicine in the Infectious Disease and Vaccines Therapeutic Area of Janssen Vaccines and Prevention BV which is part of Janssen, the pharmaceutical arm of Johnson & Johnson. She is also professor of Virology at the AMC of the University of Amsterdam. Hanneke studied medical biology at the Free University and received her PhD in Medicine in 1992 from the University of Amsterdam. She worked for over 20 years to elucidate viral and host factors in the pathogenesis of HIV infection and AIDS. In her current position, she is responsible for a portfolio of viral vaccine programs that are in the phases from Discovery to Early Development. This portfolio includes vaccine programs for Ebola, RSV, Zika and HIV.




Dr. Rosanne Hertzberger

Rosanne Hertzberger studied Life Science & Technology in Delft and Leiden. She obtained her PhD at the UvA at the Swammerdam Institute for Life Science under the supervision of Joost Teixeira de Mattos and Michiel Kleerebezem on oxygen metabolism of *Lactobacillus johnsonii*. She did a postdoc at Washington University St Louis School of Medicine in the lab of Dr. Amanda Lewis where she researched glycogen metabolism of vaginal bacteria. She is currently working as a guest researcher on the metabolism of vaginal lactic acid bacteria at VU University Amsterdam in the SysBiolab with Bas Teusink, Frank Bruggeman and Remco Kort.

In addition, she published the book *Ode to the E numbers* (2017) and *Het Grote Niets* (2019).

She writes a series on vaccination for *De Correspondent* and a weekly column in *NRC Handelsblad*.






Prof. Dr. Nigel Curtis is a scientist in medicine. He is the leader of the Infectious Diseases & Microbiology research group at the Murdoch Childrens Research Institute, Professor of Pediatric Infectious Diseases at the University of Melbourne and Head of Infectious Diseases at the Royal Children's Hospital Melbourne.

Professor Curtis completed his pre-clinical training at the University of Cambridge and clinical training at St Mary's Medical School, University of London. He completed specialized training in pediatric infectious diseases with fellowships in London and Vancouver. He also worked for a short time in The Gambia, Zimbabwe and South Africa. Curtis undertook his laboratory training at Imperial College London

St Mary's Campus, where he completed a PhD examining the role of bacterial superantigen toxins in Kawasaki disease and in staphylococcal and streptococcal toxic shock syndrome. Professor Curtis' clinical and laboratory research focuses on improving the diagnosis, treatment and prevention of infectious diseases in children. His laboratory uses the latest immunological and molecular techniques to investigate the host's immune response. He has supervised 16 PhDs, two BSc Honors, five BMedSci, seven AMS and two SS students. He has also supervised more than 40 RACP projects.

In addition to his clinical and research roles, Professor Curtis has a strong interest in the education of graduate students. He is Chair of the Department of Pediatrics Graduate Research Committee and a member of the University of Melbourne Research Higher Degree Committee and Faculty Research Training Committee.





Dr. Ir. Erwin Duizer

Erwin Duizer obtained his master degree in Cell Biology at the Agricultural University Wageningen in 1993 and his PhD after 4 years of research at TNO Food and Nutrition Research Institute in 1999 at the same university.

In 1998 he started a postdoc position at the Research Laboratory for Infectious Diseases, at the national Institute for Public Health and the Environment (RIVM). At the RIVM he worked as senior scientist on viruses and foodsafety and viruses and hygiene while taking on several management tasks in the meantime.

In 2015 he became Head of the National Polio Laboratory and WHO Specialized Reference Laboratory for Polio at the RIVM.

- 1998 –2002 Postdoc: Development of advanced human intestinal epithelial cell cultures for multiplication of enteropathogenic viruses & Molecular detection and viability screening of non-cultivable food borne viruses, Research Laboratory for Infectious Diseases, RIVM, Bilthoven.
- 2002-2015 Scientist working on “Enteric viruses and Foodsafety”, LIS, RIVM.
- 2004-2009 Assistant coordinator Food Borne Viruses in Europe (FBVE) network.
- 2005-2015 Member expert Network “Voedingscentrum”.
- Since 2006 Reviewer for several journals including the International Journal of Food Microbiology, Epidemiology and Infection, Journal of Virological Methods, Journal of Clinical Virology and Applied and Environmental Microbiology.
- 2007-2008 Projectleader gastro-enteric viruses, LIS, RIVM.
- 2008-2015 Head of section EntericViruses, IDS Virology, RIVM.
- Since 2013 board member SKML Virology section.
- Since 2015 Head of the National Polio Laboratory and WHO Specialized Laboratory for Polio, RIVM.






Prof. Dr. Meta Roestenberg

Meta Roestenberg has considerable experience in design and execution of controlled human infection studies. Trained as an infectious diseases specialist, she dedicates most of her time to leading the Leiden Controlled Human Infection Center, which harbours a group of interdisciplinary scientists studying host-pathogen interaction for a range of micro-organisms. Working mainly in the field of parasitology, the group focusses on malaria, schistosomiasis and hookworm studies, developing and testing novel vaccine candidates for these infectious diseases of global importance. The group has developed novel tools to study parasites in their early stages as they transition from one host to the other, with the use of novel imaging technologies as well as immunological assays. She is a physician-scientist working as a scientist at the research laboratories of the department of Parasitology and as clinician within the

department of Infectious Diseases. She studied Medicine at the University of Maastricht, where she obtained her medical degree cum laude in 2004. During her medical training she had the opportunity to follow internships in Africa and South-East Asia, where she became fascinated by infectious diseases. She returned to India for additional training several months after her graduation and then decided to dedicate her professional career to poverty related infectious diseases. She completed her PhD cum laude in 2013 at the department of Medical Microbiology of the Radboud University Medical Center where she developed a human model for malaria immunity. She was trained in internal medicine at the Radboud University Medical Center and the Canisius Wilhelmina Hospital, both in Nijmegen.

In 2014 she registered as Infectious Diseases specialist at the Leiden University Medical Center and was awarded a VENI grant from the Dutch Society for Scientific Research and a Gisela Thier fellowship in order to pursue translational research into the interaction between malaria parasites and the skin.

Meta Roestenberg, recently won the Heineken Young Scientists Award 2020. The prize has been awarded by the Royal Netherlands Academy of Arts and Sciences (KNAW). Meta receives the prize for her research into the development of vaccines against poverty-related infectious diseases. In the future, Meta will continue to focus on clinical translational vaccine research to fight infectious diseases that cause significant morbidity and mortality among the poorest people in the world.





Dr. Ir. Matthijs Jore

Department of Medical Microbiology Radboudumc

Postbus 9101

6500 HB Nijmegen

The Netherlands


Tel: +31 24 3610583

E-mail: Matthijs.Jore@radboudumc.nl

After completing the study Molecular Sciences (WUR), he did his PhD in the group of Prof. dr. John van der Oost (WUR) where he studied the CRISPR-Cas system in bacteria which was just discovered at that time.

Then, as a postdoc at Oxford University, he investigated how proteins in tick spit inhibit the human complement system. Using protein

crystallography, he demonstrated how these proteins bind to human complement proteins, which also led to new insights into complement activation. Since 2016, he has been working as a researcher within the malaria research group at Radboud university medical center. He leads a research team working on the preclinical development of transmission blocking vaccines and antibodies. This includes the discovery of new vaccine candidates and human antibodies, and their in vitro and in vivo validation. He also contributes to the development of a vaccine and therapeutic antibody that will soon be tested in healthy volunteers. In 2019 he received a VIDI grant from NWO to investigate how malaria parasites can escape from the human complement system and how the complement system can be used to make more effective malaria vaccines.






Professor. dr. Louis Bont

Louis Bont voltooide zijn opleiding tot kinderarts in 2005 en tot kinderarts infectioloog-immunoloog in 2008. Hij beoefent het vak in de volle breedte, waarbij er interesse is voor complexe infectieziekten, zowel wordt gezien op afdelingen als de intensive care als kinderoncologie, maar ook voor kinderen met minder ernstige, herhaalde luchtweginfectie op de vroege kinderleeftijd.

Louis werkt vanuit de visie dat ieder kind de best mogelijk medische zorg verdient. Al zijn professionele activiteiten zijn hierop gericht. Hiertoe behandelt hij patiëntjes, maar draagt ook bij aan onderwijs van medisch studenten en kinderartsen in opleiding. Bij Louis vinden patiënten een algemeen kindergeneeskundige benadering, door ook problematiek buiten de infectieziekten en immunologie krijgen aandacht te schenken. Hij probeert ook via wetenschappelijk onderzoek de zorg voor toekomstige patiënten te verbeteren.

Persoonlijke prijzen en onderscheidingen:

- 2013 International Congress of Pediatric Pulmunology (CIPP) Award for Contribution to Understanding Childhood Respiratory Disease and Global Medical Education
- 2010 Catharijnestichting Award 2010
2005 Ter Meulen Fonds lecture: "It is not all asthma that wheezes". 27e Congres Nederlandse Vereniging voor Kindergeneeskunde, Veldhoven, 2005
- 2000 Royal Dutch Academy of Science (Ter Meulen Fonds Stipendium). Immunopathogenetic mechanisms of RSV infection in the mouse model.
- 2000 ESPID Fellowship Award 2001 Immunopathogenetic mechanisms of RSV infection in the mouse mode
- Louis is geïnteresseerd in de pathogenese, preventie en behandeling van respiratoir syncytieel virus (RSV) infecties. Hij leidt de Utrecht RSV Research Group. Zijn onderzoek richt zich op de klinische, genetische en immunologische determinanten van RSV bronchiolitis. Zijn onderzoeksgroep heeft een aantal goed gedefinieerde RSV cohorten bestudeerd om inzicht te geven in de immunopathogenese van RSV infectie.
- Louis heeft bijzondere interesse in de relatie tussen RSV bronchiolitis en de ontwikkeling van lange termijn morbiditeit luchtwegklachten, zoals astma. Zijn fundamentele onderzoek richt zich op de ontwikkeling van diermodellen om de interactie tussen RSV en de mens te bestuderen. Louis Bont is de voorzitter van ReSViNET, een internationaal RSV Onderzoeksnetwerk.





Dr. Susan van den Hof

Studeerde Biomedische Wetenschappen in Nijmegen. Ze promoveerde aan de Universiteit van Utrecht op onderzoek naar de bescherming van de Nederlandse bevolking van bof, mazelen en rode hond, en onderzoeken tijdens de mazelen epidemie in 1999-2000. Ze bekleedde diverse functies op het gebied van epidemiologie en surveillance van infectieziekten bij het RIVMRijksinstituut voor Volksgezondheid en Milieu van 1996 t/m 2006. Vervolgens werkte zij bij KNCVKoninklijke Nederlandse Centrale Vereniging (voor tuberculosebestrijding) - Tuberculosis Foundation Tuberculosefonds als epidemioloog en coördinator van onderzoek, dat grotendeels in Aziatische en Afrikaanse landen plaatsvond. Sinds juli 2018 is ze terug bij het RIVM als hoofd van het Centrum voor Epidemiologie en

Surveillance van Infectieziekten.

Expertise


- Infectieziekten
- Epidemiologie
- Surveillance



Dr. Bart L. Haagmans

Bart Haagmans (1963) is a virologist, working at the Viroscience department of the Erasmus Medical Center in Rotterdam. He studied at Utrecht University and obtained his doctorate from the same university. His interest is the pathogenesis of viral infections, including SARS, MERS and the new coronavirus. The study includes the characterization of viral variants and the serological response generated in the different host species. In addition, the genomes of many other new viruses and their variants have been characterized by complete genome analysis. In recent years, for example, we have characterized the genome of the MERS coronavirus, identified the

receptor and contributed to the identification of the dromedary camel as the reservoir species. We have tested a vaccine candidate that reduces the transmission of MERS-CoV by vaccinating dromedary camels. He is currently working on further characterizing the SARS-CoV-2 virus, developing molecular and serological tests and vaccine candidates for this virus.



PRAKTISCHE INFORMATIE

Datum: 23 & 24 september 2021

Ontvangst 23 september inloop vanaf 8.30 uur tot 9.15 uur

De bijeenkomst zal zowel fysiek als gestreamd plaatsvinden

Locatie: Hotel van der Valk, Veluwezoom 45, 1327 AK Almere
tel: 036-8000800.

De organisatie is beide dagen bereikbaar op 06-21424899



Route:

Vanuit de richting Haarlem/Amsterdam (A1)

Vanaf de A1 richting Amersfoort neem je de A6 richting Almere. Op de A6 neem je afslag 5 (Almere Stad). Aan het eind van de afslag ga je linksaf richting Almere Stad (S103 Veluwedreef). Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Vanuit de richting Utrecht (A27)


Vanaf de A27 richting Hilversum/Huizen neem je afslag 36 richting Almere Stad. Aan het eind van de afslag ga je linksaf richting Almere Haven/Almere Stad (N305). Vlak voor Almere rijd je onder het viaduct van de snelweg A6 door, nog steeds richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vindt je Hotel Almere.

Vanuit de richting Lelystad (A6)

Vanaf de A6 richting Almere neem je afslag 5 (Almere Stad). Aan het eind van de afslag ga je bij het verkeerslicht linksaf richting Almere Stad (S103 Veluwedreef). Bij het 1e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Vanuit de richting Amersfoort binnendoor (A28)

Vanaf de A28 richting Zwolle neem je de afslag Nijkerk. Aan het eind van de afslag ga je bij de verkeerslichten linksaf richting Almere (N301). Bij de eerste en tweede rotonde neem je de 2e afslag, dus rechtdoor. Bij de derde rotonde ga je linksaf richting Almere (N305). Vlak voor Almere rijd je onder het viaduct van de snelweg A6 door richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vindt je Hotel Almere.



Vanuit de richting Apeldoorn / Amersfoort (A1)

Vanaf de A1 richting Amersfoort heb je twee mogelijkheden:

* Vervolg de route via de A28 en dan binnendoor (zie hierboven)

* Vervolg de route over de A1 verder richting Amsterdam. Neem bij Hilversum de afslag naar de A27 richting Almere/Huizen. Vervolg verder de route vanuit de richting Utrecht (zie boven).

Vanuit de richting Zwolle (A28)

Vanaf de A28 richting Amersfoort heb je twee mogelijkheden:

* Via Lelystad: zie route vanuit de richting Lelystad.

* Vanaf de A28 richting Amersfoort/Utrecht neem je de afslag Harderwijk. Je vervolgt uw route via de N302 richting Lelystad. Daarna vervolg je de route via de N305 richting Almere. Vlak voor Almere rijd je onder het viaduct (snelweg A6) door richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Met het openbaar vervoer:

Hotel Almere is uitstekend met het openbaar vervoer te bereiken. Treinstations Almere Parkwijk en Almere Centrum zijn per auto slechts enkele minuten van het hotel verwijderd. Vanaf deze stations kan je per bus of taxi naar het hotel reizen. Vanaf zowel Station Almere Parkwijk als Almere Centrum kan je bus M5 nemen en uitstappen bij bushalte Walt Disneyplantsoen. Vanaf deze halte is het ongeveer 10 minuten lopen naar Hotel Almere.

Deelnamekosten: De deelnamekosten bedragen € 295 per persoon. Dit bedrag is inclusief diner, lunches, koffie, thee en afsluitende borrel maar exclusief overnachtingskosten.

Inschrijving voor fysieke of online deelname: zie de website:

<https://vaccinologymasterclass.org/vaccin-masterclass-voor-infectiologen-en-onderzoekers-2021/>

Hotelovernachting:

Overnachten bij Hotel Van der Valk is mogelijk tegen een gereduceerd tarief van 120 euro per kamer. Je kunt bij het inschrijven aangeven of je van deze mogelijkheid gebruik wilt maken.


Wij hebben 20 kamers in optie genomen en de optie verloopt half September. Wacht daarom niet te lang.

Lunches en diner: Wij houden graag rekening met dieetrestricties.

Wil je deze uiterlijk 20 september doorgeven aan de organisatie van de twee-daagse: Info@gerhardbruggink.nl.

Mailing en adressering: Graag houden wij je op de hoogte van voor jou interessante bijeenkomsten en diensten. Je bent daartoe opgenomen in ons adressenbestand. Dit bestand zal nooit ter beschikking gesteld worden aan derden.

Tot 23 september in Almere! (of online)



VACCINOLOGY MASTERCLASS

SPONSOR INFORMATIE

De Stichting Vaccinology Masterclass wordt financieel ondersteund door GlaxoSmithKline, Pfizer, Sanofi Pasteur en MSD. Deze bedrijven hebben op geen enkele manier invloed op de inhoud van het programma. De Stichting en de Faculty zijn de bedrijven zeer erkentelijk voor hun ondersteuning.



GlaxoSmithKline, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort



Pfizer, Rivium Westlaan 142, 2909 LD Capelle a/d IJssel



Sanofi Pasteur, Paasheuvelweg 25, 1105 BP Amsterdam



MSD, Waarderweg 39, 2031 BN Haarlem

